Palo Santo, a venture fund focused on psychedelic therapeutics and a Ksana Health investor, took a survey of the perspectives of a number of thought leaders in the psychedelics space in light of the ongoing crisis of distress and violence going on in the US. One of the thought leaders was Ksana Health founder, Dr. Nick Allen, PhD. The healthful potential of psychedelics will be limited if ethical and complementary technologies are not used alongside them.
At Ksana Health, we believe in the potential of continuous behavior measurement & intervention to provide treaters and the treated a richer insight into the moment-to-moment experience and effect of psychedelic therapy. This rich real-world measurement will make for better therapeutic experiences, optimizations, and alliances. We have recently entered an agreement with Beckley PsyTech to aid their Phase 2 trials.
19 August 2022
Like any new health technology, continuous behavioral health measurement (CBHM) must economically justify its place among the growing options for measuring therapy and care outcomes. At Ksana Health, we think a lot...Continue reading
In September 2022, Ksana Health founders, Dr. Nick Allen and Will Short are quoted in an industry article highlighting the opportunistic role of remote patient monitoring (RPM) in behavioral health. Ideas...Continue reading
Ksana Health completed its first third-party assessment for security and privacy controls, receiving unqualified approval attesting to the strength of our controls and compliance with best practices and statutory requirements, including: AICPA,...Continue reading